['multiple myeloma']
['carfilzomib/lenalidomide/dexamethasone']

        Inclusion Criteria:

          -  Patients diagnosed with multiple myeloma based on the new International Myeloma
             Working Group

          -  Subjects must have symptomatic myeloma with at least one CRAB criteria

          -  Subjects must not have been treated previously with any systemic therapy for multiple
             myeloma

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Evidence of mucosal or internal bleeding and/or platelet refractory

          -  Acute active infection requiring treatment

          -  Treatment by localized radiotherapy if the interval between the end of radiotherapy
             and initiation of protocol therapy lower than 2 weeks

          -  Treatment by corticosteroids if exceed the equivalent of 160 mg of dexamethasone in a
             2-week period before initiation therapy

          -  Subjects not eligible for high dose therapy
      